Physician profile
Crystal Janani
NPI 1902119415
$2,813.62
in general payments reported to CMS, 2019-2025
27 companies · $994 in 2025
The $994 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $627 · 2020: $120 · 2021: $141 · 2023: $396 · 2024: $536 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,913 · Education: $13.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,912.57 |
| Education | $13.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $349.77 | 2023-2025 | |
| Sk Life Science, INC. | $319.99 | 2021-2025 | Xcopri |
| Abbvie INC. | $303.62 | 2023-2025 | |
| Lundbeck LLC | $231.06 | 2019-2025 | Vyepti |
| Horizon Therapeutics Plc | $223.41 | 2023 | Uplizna |
| Eisai INC. | $182.31 | 2024-2025 | |
| Allergan, INC. | $161.49 | 2019-2020 | |
| Neurelis, INC. | $130.54 | 2020-2025 | Valtoco |
| Ucb, INC. | $116.85 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $114.05 | 2019-2025 | Austedo Xr |
| Lilly USA, LLC | $100.96 | 2019 | |
| Amgen INC. | $79.82 | 2019-2025 | Uplizna |
| Aucta Pharmaceuticals, INC. | $69.01 | 2024-2025 | Motpoly Xr |
| Medtronic USA, INC. | $67.76 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $62.82 | 2023-2024 | Aptiom |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $45.79 | 2019 | |
| Biogen, INC. | $44.34 | 2019 | |
| Celgene Corporation | $39.20 | 2023-2025 | Zeposia |
| Tanabe Pharma America, INC. | $23.78 | 2025 | Radicava |
| Catalyst Pharmaceuticals, INC. | $23.41 | 2024 | |
| Acorda Therapeutics, INC | $22.93 | 2019 | |
| Livanova USA, INC. | $18.96 | 2019 | |
| Acadia Pharmaceuticals INC | $18.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.11 | 2019 | |
| Csl Behring | $17.86 | 2019 | |
| Vanda Pharmaceuticals INC. | $15.03 | 2025 | Ponvory |
| Bausch Health US, LLC | $11.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Janani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.